Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement

• Main Authors: Rudolf Weide, Roland Schnell, Christof Schardt, Michael Koenigsmann, Burkhard Otremba, Mark-Oliver Zahn, Jan Wierecky, Ute Braun, Manfred Hensel, Martine Klausmann, Doris Fleckenstein, Peter Ehscheidt, Stefan Feiten
• Format: Article
• Language: English
• Published: BMC 2020-06-01
• Series: BMC Immunology
• Subjects: Immunoglobulin G deficiencies; IgG replacement; Infections; Perceived health; Outpatient treatment
• Online Access: http://link.springer.com/article/10.1186/s12865-020-00368-7

Abstract Background The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis. Methods Patients with symptomatic primary or secondary IgG deficiencies were interviewed prior to the first IgG infusion (t0) and over the course of their treatment (t1 - t6). The respondents rated their current health using a 100 point scale (EQ-5D-5L), ranging from 0 (‘worst imaginable health’) to 100 (‘best imaginable health’). The patients also provided information on the frequency of infections and of infections requiring antibiotics in the past 8 weeks. A healthy control group (CG) without oncologic diseases answered the questions once. Results One hundred six patients with a median age of 65 years (21–85 years) were investigated. The median serum IgG concentration changed from 500 mg/dl (t0) to 772 mg/dl (t6). The mean number of infections and of infections requiring antibiotics decreased during IgG replacement significantly. Current health according to EQ-5D-5L improved from 57 (t0) to 68 (t6), compared to 73 in the CG. Conclusion During the course of IgG replacement patients reported fewer and less severe infections. Their health assessment improved but still was inferior to the healthy CG.